Friedman et al. corroborated the synergistic effect of SBRT (30 Gy in three fractions) and anti-PD-1 combination in an orthotopic murine HCC model resulting in tumor growth suppression, longer survival, and more profuse infiltration of CD8+ cytotoxic T cells within the tumor [126]. The gene discussed is CD8A; the disease is neoplasm.